1. Biotechnology

Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks

Written by Posted on Less than 0 min read

A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study.

Member since

More from BioPharma Dive staff

Next
No Comments
Leave a comment Cancel
Comments to: Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.